Credit Suisse Group reiterated their outperform rating on shares of Humana Inc. (NYSE:HUM) in a report issued on Thursday, July 13th. Credit Suisse Group currently has a $250.00 target price on the insurance provider’s stock, up from their previous target price of $245.00.
HUM has been the topic of several other research reports. Zacks Investment Research raised Humana from a hold rating to a buy rating and set a $256.00 target price on the stock in a research report on Monday, May 8th. Deutsche Bank AG initiated coverage on Humana in a research report on Wednesday, April 5th. They set a hold rating and a $216.00 target price on the stock. Argus upgraded Humana from a hold rating to a buy rating and set a $260.00 price objective for the company in a report on Friday, June 9th. Oppenheimer Holdings, Inc. initiated coverage on Humana in a report on Thursday, March 30th. They set an outperform rating and a $236.00 price objective for the company. Finally, Cantor Fitzgerald boosted their price objective on Humana from $190.00 to $200.00 and gave the company a neutral rating in a report on Wednesday, April 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the stock. The stock has an average rating of Buy and a consensus target price of $243.65.
Shares of Humana (HUM) traded down 0.67% during trading on Thursday, hitting $249.99. 840,299 shares of the stock traded hands. The stock has a 50 day moving average price of $239.25 and a 200-day moving average price of $222.56. Humana has a 1-year low of $163.50 and a 1-year high of $255.27. The stock has a market cap of $36.13 billion, a price-to-earnings ratio of 20.57 and a beta of 0.91.
Humana (NYSE:HUM) last released its earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.08 by $0.41. The firm had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same quarter in the previous year, the company posted $2.30 EPS. Equities analysts forecast that Humana will post $11.55 EPS for the current year.
WARNING: This piece was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/08/11/humana-inc-hum-rating-reiterated-by-credit-suisse-group-updated-updated-updated.html.
In related news, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total value of $1,193,040.00. Following the completion of the sale, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Heidi S. Margulis sold 1,500 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $231.96, for a total value of $347,940.00. Following the completion of the sale, the vice president now directly owns 8,150 shares of the company’s stock, valued at approximately $1,890,474. The disclosure for this sale can be found here. Corporate insiders own 0.80% of the company’s stock.
Large investors have recently bought and sold shares of the company. Guardian Life Insurance Co. of America boosted its stake in Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares during the period. Reliance Trust Co. of Delaware boosted its stake in Humana by 0.7% in the second quarter. Reliance Trust Co. of Delaware now owns 1,123 shares of the insurance provider’s stock valued at $270,000 after buying an additional 8 shares during the period. Creative Planning boosted its stake in shares of Humana by 0.3% in the second quarter. Creative Planning now owns 4,874 shares of the insurance provider’s stock worth $1,173,000 after buying an additional 15 shares during the last quarter. Cadence Capital Management LLC boosted its stake in shares of Humana by 0.4% in the second quarter. Cadence Capital Management LLC now owns 5,682 shares of the insurance provider’s stock worth $1,367,000 after buying an additional 22 shares during the last quarter. Finally, Sit Investment Associates Inc. boosted its stake in shares of Humana by 0.3% in the second quarter. Sit Investment Associates Inc. now owns 12,020 shares of the insurance provider’s stock worth $2,892,000 after buying an additional 40 shares during the last quarter. 99.66% of the stock is owned by institutional investors.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
What are top analysts saying about Humana Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Humana Inc. and related companies.